Related Experiment Video
Updated: May 5, 2026

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
Published on: July 28, 2023
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical
T Ohkusa1, I Takashimizu, K Fujiki
1Tokyo Medical and Dental University School of Medicine, Japan. ohmed1@med-tmd.ac.jp
Background:
Helicobacter pylori infection is common in patients with hyperplastic gastric polyps.
Objective:
To study the effect of eradication of H. pylori on the clinical course of patients with hyperplastic gastric polyps.
Design:
Single-blind, randomized, controlled trial.
Setting:
University-based gastroenterology outpatient clinic.
Patients:
35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter.
Intervention:
Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment.
Measurements:
Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured.
Results:
In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 +/- 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01).
Conclusions:
Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.
More Related Videos
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer
Gastritis II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology

